Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multi‐center, open‐label, 52‐week phase 3 trial

Intravenous immunoglobulin (IVIg) therapy is currently the only established treatment in patients with multifocal motor neuropathy (MMN), and many patients have an IVIg‐dependent fluctuation. We aimed to investigate the efficacy and safety of every 3 week IVIg (1.0 g/kg) for 52 weeks. This study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuwabara, Satoshi, Misawa, Sonoko, Mori, Masahiro, Iwai, Yuta, Ochi, Kazuhide, Suzuki, Hidekazu, Nodera, Hiroyuki, Tamaoka, Akira, Iijima, Masahiro, Toda, Tatsushi, Yoshikawa, Hiroo, Kanda, Takashi, Sakamoto, Ko, Kusunoki, Susumu, Sobue, Gen, Kaji, Ryuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2018
Materias:
Research Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033107/
https://www.ncbi.nlm.nih.gov/pubmed/29635876
http://dx.doi.org/10.1111/jns.12268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033107/
https://www.ncbi.nlm.nih.gov/pubmed/29635876
http://dx.doi.org/10.1111/jns.12268

Ejemplares similares